Mercer Global Advisors
RAPP

Mercer Global Advisors’s Rapport Therapeutics RAPP Stock Holding History

Mercer Global Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.6K Buy
+519
New +$19.1K ﹤0.01% 4779

Other funds holding RAPP

TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TGV
TRV GP VI Boston, Massachusetts $232M AUM 247.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Mercer Global Advisors's RAPP Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Rapport Therapeutics (RAPP) in Q2 2026: 519 shares worth $21.6K. The stake represents ﹤0.01% of the portfolio and ranks #4779 among its holdings.

125 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Mercer Global Advisors held 519 shares of Rapport Therapeutics worth $21.6K as of Q2 2026.
  • Rapport Therapeutics was a new Mercer Global Advisors position in Q2 2026.
  • Rapport Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4779 holding.
  • 125 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.